MedTrace Logo

A Study of Efficacy, Safety, Tolerability of LXE408 in Participants With Chronic Chagas Disease.

NCT06632600 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2026-03-30

No results posted yet for this study

Summary

This study is to investigate the ability of LXE408 to clear or reduce the level of parasites in the blood of people with chronic Chagas disease. Participants must have chronic Chagas disease without severe organ dysfunction.

Conditions

  • Chagas Disease

Interventions

DRUG

LXE408

LXE408 administered by oral route

DRUG

Placebo

Placebo administered by oral route

DRUG

Benznidazole

Benznidazole administered by oral route (administered as standard of care)

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-28
Primary Completion
2027-03-22
Completion
2030-09-21
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • Colombia

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06632600 on ClinicalTrials.gov